首页> 外文期刊>Theranostics >Thrombus-Targeted Theranostic Microbubbles: A New Technology towards Concurrent Rapid Ultrasound Diagnosis and Bleeding-free Fibrinolytic Treatment of Thrombosis
【24h】

Thrombus-Targeted Theranostic Microbubbles: A New Technology towards Concurrent Rapid Ultrasound Diagnosis and Bleeding-free Fibrinolytic Treatment of Thrombosis

机译:血栓靶向的治疗性微泡:并行快速超声诊断和无出血纤溶治疗血栓形成的新技术。

获取原文
           

摘要

Rationale: Myocardial infarction and stroke are leading causes of morbidity/mortality. The typical underlying pathology is the formation of thrombi/emboli and subsequent vessel occlusion. Systemically administered fibrinolytic drugs are the most effective pharmacological therapy. However, bleeding complications are relatively common and this risk as such limits their broader use. Furthermore, a rapid non-invasive imaging technology is not available. Thereby, many thrombotic events are missed or only diagnosed when ischemic damage has already occurred. Objective: Design and preclinical testing of a novel 'theranostic' technology for the rapid non-invasive diagnosis and effective, bleeding-free treatment of thrombosis. Methods and Results: A newly created, innovative theranostic microbubble combines a recombinant fibrinolytic drug, an echo-enhancing microbubble and a recombinant thrombus-targeting device in form of an activated-platelet-specific single-chain antibody. After initial in vitro proof of functionality, we tested this theranostic microbubble both in ultrasound imaging and thrombolytic therapy using a mouse model of ferric-chloride-induced thrombosis in the carotid artery. We demonstrate the reliable highly sensitive detection of in vivo thrombi and the ability to monitor their size changes in real time. Furthermore, these theranostic microbubbles proofed to be as effective in thrombolysis as commercial urokinase but without the prolongation of bleeding time as seen with urokinase. Conclusions: We describe a novel theranostic technology enabling simultaneous diagnosis and treatment of thrombosis, as well as monitoring of success or failure of thrombolysis. This technology holds promise for major progress in rapid diagnosis and bleeding-free thrombolysis thereby potentially preventing the often devastating consequences of thrombotic disease in many patients.
机译:理由:心肌梗塞和中风是发病/死亡的主要原因。典型的基础病理是血栓/栓塞的形成以及随后的血管闭塞。全身给药的纤溶药物是最有效的药理疗法。但是,出血并发症相对普遍,这种风险限制了它们的广泛使用。此外,没有快速的非侵入性成像技术。因此,许多血栓事件被遗漏或仅在已经发生缺血性损害时才被诊断。目的:设计和临床前测试一种新颖的“ theranostic”技术,用于快速无创诊断和有效,无出血的血栓形成治疗。方法和结果:一种新创建的创新性治疗学微泡将重组纤溶蛋白药物,增强回声的微泡和重组血栓靶向装置以活化的血小板特异性单链抗体的形式结合在一起。在初步的功能体外证明之后,我们使用氯化铁诱发的颈动脉血栓形成小鼠模型,在超声成像和溶栓治疗中测试了该治疗性微泡。我们证明了体内血栓的可靠的高灵敏度检测和实时监测其大小变化的能力。此外,这些治疗疗法的微泡被证明与商业尿激酶在溶栓治疗中一样有效,但没有尿激酶所见的出血时间延长。结论:我们描述了一种新颖的治疗术技术,能够同时诊断和治疗血栓形成,并监测溶栓的成功或失败。这项技术有望在快速诊断和无出血血栓溶解方面取得重大进展,从而有可能预防许多患者血栓性疾病的灾难性后果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号